News articles about Vermillion (NASDAQ:VRML) have trended somewhat positive on Saturday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vermillion earned a news impact score of 0.02 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.1530542716533 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference (finance.yahoo.com)
- Reimbursement cuts on lab tests pressure US lab firm shares (LH, DGX, GNMK, GHDX, VRML) (markets.businessinsider.com)
- ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1 (finance.yahoo.com)
- Vermillion Announces Publication of Foundational Health Economics Study (finance.yahoo.com)
Vermillion (NASDAQ VRML) opened at $1.79 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.74 and a quick ratio of 3.67. Vermillion has a 12 month low of $0.91 and a 12 month high of $2.85.
VRML has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Vermillion from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Canaccord Genuity reiterated a “buy” rating and issued a $1.75 price objective (down previously from $2.50) on shares of Vermillion in a research note on Wednesday, August 30th.
ILLEGAL ACTIVITY NOTICE: “Vermillion (VRML) Receiving Somewhat Favorable Media Coverage, Analysis Shows” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/11/25/vermillion-vrml-receiving-somewhat-favorable-media-coverage-analysis-shows.html.
Vermillion Company Profile
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with MarketBeat.com's FREE daily email newsletter.